Phase 2a clinical trial evaluating REG-101 for PAD expected to initiate second half of 2022 ROCKVILLE, Md.–(BUSINESS WIRE)–Regio Biosciences (Regio), a Hibiscus BioVentures company, announced today it has entered into an exclusive license agreement with AstraZeneca to further develop REG-101, a novel therapeutic acting […]
